However, our results demonstrate that GLP-1RAs reduce cholesterol levels in culture media, decrease PCSK9 gene expression, and elevate LDLR gene expression in PA-treated HepG2 cells
Safety Comparisons The safety issues, including withdrawal ( n = 9,881) (Figure 4A), serious AE ( n = 8,779) (Figure 4B), gastrointestinal side effects ( n = 6,566) (Figure 4C), hypoglycemia ( n = 9,179) (Figure 4D), overall AEs ( n = 8,982) (Figure 4E), nasopharyngitis ( n = 2,199) (Figure 4F), dizziness ( n = 3,194) (Figure 4G), and upper respiratory infection ( n = 2,175) (Figure 4H) were compared across all the interventions (rank probabilities are shown in Figure S7)
This is a condition where excess fat builds up in a persons liver, not due to heavy alcohol use
Wilding JP, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al
A randomized trial study on GLP-1 liraglutide in the New England Journal of Medicine showed the effectiveness of treating obesity in children aged 6 to 12 years
After 10 years, those who had surgery showed significantly better outcomes, including a: 32% lower risk of death 35% lower risk of major heart problems (such as heart attack, heart failure, or stroke) 47% lower risk of serious kidney disease 54% lower risk of diabetes-related eye damage (retinopathy) On average, surgical patients lost 21.6% of their body weight, compared with 6.8% among those taking GLP-1 medicines
